Nkarta Announces September 2020 Virtual Investor Conference Schedule
Nkarta, Inc. (Nasdaq: NKTX) will participate in the Cantor Virtual Global Healthcare Conference on September 15, 2020, with a fireside chat presentation scheduled for 2:00 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nkarta, Inc. (Nasdaq: NKTX) will participate in the Cantor Virtual Global Healthcare Conference on September 15, 2020, with a fireside chat presentation scheduled for 2:00 p.m. ET. The event will feature a live audio webcast available on Nkarta's website, with a replay archived for approximately four weeks.
Nkarta is focused on developing engineered natural killer (NK) cell therapies for cancer, utilizing a proprietary platform for efficient manufacturing and cell engineering aimed at enhancing tumor targeting and persistence.
Positive
- Participation in a notable investor conference could enhance visibility and investor interest.
- Focus on engineered NK cell therapies positions Nkarta in a promising area of oncology.
Negative
- None.
Details
News Market Reaction – NKTX
The recorded move for NKTX in the trading session of this news was +6.91%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it will participate at the following virtual investor conference:
Cantor Virtual Global Healthcare Conference
Date: Tuesday, September 15, 2020
Fireside chat presentation: 2:00 p.m. ET
A live audio webcast of the event will be available on the Investors section of Nkarta’s website, www.nkartatx.com. A replay of the webcast will be archived on the website for approximately four weeks.
About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic natural killer (NK) cell therapies for cancer. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of cell therapy candidates generated by efficient manufacturing processes, and engineered to enhance tumor targeting and improve persistence for sustained activity in the body. For more information, please visit the company’s website at www.nkartatx.com.
Nkarta Media/Investor Contact:
Greg Mann
Nkarta, Inc.
gmann@nkartatx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.